Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mind Medicine Inc (MMED.NE)

Mind Medicine Inc (MMED.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Mind Medicine Inc One World Trade Center Suite 8500 New York NY 10007 USA

https://www.mindmed.co P: 212-220-6633

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Key Statistics

Overview:

Market Capitalization, $K 1,050,465
Shares Outstanding, K 70,501
Annual Sales, $ 0 K
Annual Net Income, $ -108,679 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -34,741 K
60-Month Beta 3.49
% of Institutional Shareholders 2.38%

Growth:

1-Year Return 265.20%
3-Year Return -67.32%
5-Year Return 0.00%

Per-Share Information:

Most Recent Earnings -0.59 on 11/02/23
Next Earnings Date N/A
Earnings Per Share ttm -2.44
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 08/29/22

MMED.NE Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -68.01%
Return-on-Assets % -50.94%
Profit Margin % 0.00%
Debt/Equity 0.09
Price/Sales N/A
Price/Book 9.91
Book Value/Share 1.50
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar